Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis

Similar documents
Diagnosis of TB: Laboratory Ken Jost Tuesday April 9, 2013

CDC s Approach to Fast Track Laboratory Diagnosis for Persons at Risk of Drug Resistant TB: Molecular Detection of Drug Resistance (MDDR) Service

Diagnosis of TB: Laboratory Ken Jost Tuesday April 1, 2014

Laboratory Diagnosis for MDR TB

Pyrosequencing Experience from Mumbai, India. Camilla Rodrigues MD Consultant Microbiologist Hinduja Hospital,Mumbai India

Ken Jost, BA, has the following disclosures to make:

MIC = Many Inherent Challenges Sensititre MIC for Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis complex

TB Nurse Case Management. March 7-9, Diagnosis of TB: Ken Jost Wednesday March 7, 2012

TB Intensive San Antonio, Texas November 11 14, 2014

Stacy White, PhD May 12, TB for Community Providers. Phoenix, Arizona

Rapid Diagnostic Techniques for Identifying Tuberculosis Ken Jost November 13, 2008

Shah: Discordant Growth- Molecular Rifampin Resistance 2/27/16 RELAPSED FAILED

DST for detection of DR TB - roll out of Xpert in South Africa and overview of other technologies: what are the gaps?

When good genes go bad

Drug susceptibility testing for tuberculosis KRISTEN DICKS, MD, MPH DUKE UNIVERSITY MEDICAL CENTER

TB 101 Disease, Clinical Assessment and Lab Testing

Molecular tests for rapid detection of rifampicin and isoniazid resistance in Mycobacterium tuberculosis.

TB is Local. Barry Chin, Boston Globe, 10/15/2008. * BUT only in appropriate setting

Experts on Xpert: A laboratorian and a clinician discuss interpretation of Xpert MTB/RIF Results

TB Updates for the Physician Rochester, Minnesota June 19, 2009

The Molecular MDR Screen is an Important Tool in the Diagnosis and Initiation of Appropriate Therapy in TB Patients in the State of Florida

Molecular assays in Tuberculosis. Jatin Yegurla Junior resident

Laboratory Diagnosis and Antimicrobial Susceptibility Testing of Mycobacterium tuberculosis Complex. Objectives

Laboratory s Role in the Battle Against Drug Resistant Tuberculosis

CDPH - CTCA Joint Guidelines Guideline for Micobacteriology Services In California

WELCOME. Lab Talk: What a Nurse Hears. April 18, NTNC Annual Meeting Lab Talk: What a Nurse Hears

Rapid Diagnosis of Extensively Drug-Resistant Tuberculosis by Use of a Reverse Line Blot Hybridization Assay

Diagnosis and Management of Active Tuberculosis

Diagnosis of drug resistant TB

DNA sequencing for the confirmation of rifampin resistance detected by Cepheid Xpert

Communication between clinician and laboratory Molecular detection of M. tuberculosis complex

TB/HIV 2 sides of the same coin. Dr. Shamma Shetye, MD Microbiology Metropolis Healthcare, Mumbai

A Rapid and Sensitive Chip-based Assay for Detection of rpob Gene Mutations Conferring Rifampicin Resistance in Mycobacterium tuberculosis (TB).

Overview of Mycobacterial Culture, Identification, and Drug Susceptibility Testing

Rapid Diagnosis and Detection of Drug Resistance in Tuberculosis

General Session IV - Dale Schwab April 20, 2017

Online Annexes (5-8)

NAAT in the Clinical Laboratory and Impact on Infection Control 9 th National Conference on Laboratory Aspects of Tuberculosis APHL

Mycobacteria Diagnostic Testing in Manitoba. Dr. Michelle Alfa Medical Director, DSM Clin Micro Discipline

Health Care Worker Training on Roll Out New TB Diagnostic Test. Prepared by: City Health (J Caldwell) & NHLS (M Bosman & I Noordien)

Research Article Use of Genotype MTBDRplus Assay for Diagnosis of Multidrug-Resistant Tuberculosis in Nepal

Molecular Methods in the Diagnosis of Drug Resistant Tuberculosis. Dr Sahajal Dhooria

Epidemiology and diagnosis of MDR-TB in children H Simon Schaaf

Detection of Multidrug Resistance and Characterization of Mutations in Mycobacterium tuberculosis Isolates in Raichur District, India

Principles of laboratory diagnosis of M. tuberculosis. Anne-Marie Demers, MD, FRCPC 11 September 2017

Kritische Fragen zum Beitrag der kombinierten PCR für den Nachweis von M. tuberculosis und der Identifizierung von Mutationen auf dem rpob-gen

Online Annexes (5-8)

The Molecular Epidemiology of Tuberculosis

PCR and direct amplification for tuberculosis diagnosis. Emmanuelle CAMBAU University Paris Diderot, APHP, Saint Louis-Lariboisière Hospital,

The current state of knowledge: genotypic vs phenotypic drug-susceptibility testing (DST)

Frances Jamieson, MD and Kevin May, BSc November 15 th,

TB NAAT testing at the Los Angeles County Public Health Laboratory

Xpert MTB/RIF Ultra: Understanding this new diagnostic and who will have access to it

WSLH Testing and Surveillance Updates

Received 4 June 2013; Final revision 1 August 2013; Accepted 30 August 2013; first published online 27 September 2013

Microbiological Pathology, Sefako Makgatho Health Science University, Pretoria, South Africa 2

The ABC s of AFB s Laboratory Testing for Tuberculosis. Gary Budnick Connecticut Department of Public Health Mycobacteriology Laboratory

Analysis. Answers. Action. Saturday Night Fever. Shaka Brown Capital Congress

Wei-Lun Huang,* Ting-Lin Chi, Mei-Hua Wu, and Ruwen Jou*

Nucleic Acid Amplification Test for Tuberculosis. Heidi Behm, RN, MPH Acting TB Controller HIV/STD/TB Program Oregon, Department of Health Services

How best to structure a laboratory network with new technologies

Diagnosis of tuberculosis

TB Laboratory for Nurses

Xpert MTB/RIF Training. Indira Soundiram 2012

Receipt within 1 day of specimen collection. Report AFB b smear result within 1 day from receipt of specimen

HHS Public Access Author manuscript Int J Tuberc Lung Dis. Author manuscript; available in PMC 2016 April 01.

Multi-country surveillance project on fluoroquinolones and PZA resistance

Optimising patient care in MDR TB with existing molecular screening tests in high burden countries

POSITIONING OF TB DX : TIERED SYSTEM, INTEGRATED APPROACH

A retrospective evaluation study of diagnostic accuracy of Xpert MTB/RIF assay, used for detection of Mycobacterium tuberculosis in Greece

Use of the Cepheid GeneXpert to Release Patients from Airborne Isolation

Whole Genome Next Genera/on Sequencing of TB in a Public Health Laboratory: A New Diagnos/c Era

Research Methods for TB Diagnostics. Kathy DeRiemer, PhD, MPH University of California, Davis Shanghai, China: May 8, 2012

Objectives. TB Laboratory Methods

Elizabeth A. Talbot MD Assoc Professor, ID and Int l Health Deputy State Epidemiologist, NH GEISELMED.DARTMOUTH.EDU GEISELMED.DARTMOUTH.

Nucleic Acid Amplification Testing for the Diagnosis of TB

Maha R Farhat, MD MSc Massachusetts General Hospital Harvard Medical School. I have no financial or other potential conflicts of interest to disclose

Prevalence and molecular characteristics of drug-resistant Mycobacterium tuberculosis in Beijing, China: 2006 versus 2012

White Paper Application

Evaluation of the MTBDRsl Test for Detection of Second-Line-Drug Resistance in Mycobacterium tuberculosis

Author s response to reviews Title: Bacterial risk factors for treatment failure and relapse among patients with isoniazid resistant tuberculosis

Evaluation of Genxpert Real Time PCR POC in the Diagnosis of Multidrug Resistant TB Among Patients Attending NTBLTC Saye-Zaria Nigeria

Jillian Dormandy, BS; Akos Somoskovi, MD, PhD; Barry N. Kreiswirth, PhD; Jeffrey R. Driscoll, PhD; David Ashkin, MD; and Max Salfinger, MD

Bedaquiline and delamanid combination as part of a MDR-TB treatment regimen: Current evidence and practices

AN EVALUATION OF CURRENT DIAGNOSTIC METHODS FOR TUBERCLOSIS IN RESOURCE-POOR AREAS AND A PROPOSAL FOR A MORE SENSITIVE TEST. Helen Marya McGuirk

Analysis of mutational pattern in multidrug resistant tuberculosis (MDR TB) in a geographically isolated northeastern region of India

Alere q A Molecular Platform for Global Health Diagnostics

The Clinical Impact of Rapid Nucleic Acid Amplification Tests for Detection of M. tuberculosis

Diagnosis of tuberculosis in children

GLI model TB diagnostic algorithms

Online Annexes (2-4)

TB Laboratory Services

LABORATORY METHODS: TUBERCULOSIS DIAGNOSIS

Towards Harmonization of Mycobacteriology in TB Trials. Study 31/ACTG 5349 Key Elements of Mycobacteriology Laboratory Procedures

LABORATORY BASED DST FOR BEDAQUILINE AND INTRODUCTION IN COUNTRIES

Annex 1. Methods for evidence reviews and modelling

Recognizing MDR-TB in Children. Ma. Cecilia G. Ama, MD 23 rd PIDSP Annual Convention February 2016

Progress Report March 2016

Detection of heteroresistant Mycobacterium tuberculosis by pyrosequencing

Management of MDR TB. Dr Priscilla Rupali MD; DTM&H Professor and Head Department of Infectious Diseases Christian Medical College Vellore

Transcription:

Harmonizing the Use of Molecular & Culture-based DST of Mycobacterium tuberculosis Grace Lin, MS. Research Scientist grace.lin@cdph.ca.gov APHL 8 th TB Lab Conference San Diego 8-19-13

Harmonizing? There must be some conflicts? Yes! Nothing is perfect, but each has its strength! How to make best of both methods to achieve the goal of providing timely, accurate DST results to clinicians that is the work of harmonizing! G Lin 8th TB lab conf 8-19-13 2

Disclaimer No financial affiliation with the companies whose products will be discussed in this presentation. G Lin 8th TB lab conf 8-19-13 3

Acronyms DST: Drug susceptibility testing MDST: Molecular DST CDST: Culture-based DST AP: agar proportion method DR/DS: drug resistance/susceptibility SQ: sequencing or sequence TAT: turnaround time G Lin 8th TB lab conf 8-19-13 4

What are not in harmony? MDST detected no mutations; CDST tested R. MDST detected a mutation; CDST tested S. Discrepancies occur: between CDST methods: AP & MGIT disagree between labs or within lab, by different methods or even the same method. Discrepancies between MDST methods. Which result to trust? Headaches for clinicians! G Lin 8th TB lab conf 8-19-13 5

Comparison MDST CDST TAT Fast (1-3 days) Slow (weeks) Availability Limited drugs Most drugs Requires pure and viable cultures Sensitivity & Specificity No Not 100% Yes G Lin 8th TB lab conf 8-19-13 6

MDST--benefits Quick screening for DR No mutations detected, it provides good prediction for DS and confidence for continuation of standard regimen. Provides quick results for mixed or contaminated cultures, or negative cultures if smear-positive sediments are available. Provides quick confirmation of DR found by CDST. Rule in DR, if mutations detected. G Lin 8th TB lab conf 8-19-13 7

CDST we still need it! CDST results, if correct, overrides MDST results Sensitivity of MDST is not 100% MDST detected no mutations, CDST can still be R. Need to verify CDST results are correct if in doubt, re-test making sure culture is pure & DST is properly performed. Specificity of MDST is not 100% MDST detected mutations but CDST can be S. Need to recognize those mutations silent mutations & others Some MDST methods do not have this capability. Association of some mutations with DR is not certain. Need to rely on CDST. [more to discuss] G Lin 8th TB lab conf 8-19-13 8

MDST methods Probe-based Molecular beacons (GeneXpert) Xpert got FDA-approval last month! Line-probes (HAIN & LIPA) SQ-based Sanger sequencing Pyrosequencing G Lin 8th TB lab conf 8-19-13 9

What to expect from various MDST methods Molecular beacons Mutation present or absent. Line-probes Few bands with specific mutations. Presence or absence of wildtype bands. SQ methods Provide SQ. Allow to identify specific mutations known & new. G Lin 8th TB lab conf 8-19-13 10

GeneXpert (GX) For identification of MTB & detection of RIF-R Simple, fast hand-on time: few minutes. Testing raw specimens in 2 hr. Performance Identification of MTBC Sensitivity: Smear +: 98.2%; Smear-: 72.5% Specificity: 99.2% Detection of RIF-R Sensitivity: 97.6% Specificity: 98.1% Reference: Rapid molecular detection of TB & RIF resistance. NEJM 2010;363:1005-1015. Boehme et al. Be aware: there are limitations! G Lin 8th TB lab conf 8-19-13 11

Detection of Mutations with a Molecular Beacon (Loop portion containing wildtype SQ) Mutant Sequence Wildtype Sequence + Amplicon Fluorophore Light Loop Quencher Fluorophore Heat No mutations Mutation present Courtesy of Dr. Probert G Lin 8th TB lab conf 8-19-13 12

Line Probe Assays Amplification of the target Traditional PCR; one primer is biotinylated. Reverse hybridization ssdna-biotin hybridize to probes on membrane, if complementary. Colorimetric detection Observe presence or absence of bands. G Lin 8th TB lab conf 8-19-13 13

MTBC 516gtc 526tac,gac 531 ttg 315 acc 315 aca MTBDRplus by HAIN Conjugate ctrl Amplification ctrl rpob locus ctrl rpob wild-type bands 4 rpob mutations katg locus ctrl katg wild-type 2 katg mutations LiPA RIF.TB by INNOGENETICS marker line MTBC -15T -16G -8 C -8 A inha locus ctrl inha wild-type 4 inha mutations Colored marker Detect presence or absence of mutations & a few specific mutations. G Lin 8th TB lab conf 8-19-13 14

MTBDRsl by HAIN XDR Wildtype MTBC 90gtg 91ccg 94gcc 94aac, tac 94ggc 94cac 1401 G 1484 T 306ata 306gtg Conjugate ctrl Amplification ctrl gyra locus ctrl gyra wild-type bands gyra mutations rrs locus ctrl rrs wild-type bands rrs mutations embblocus ctrl embbwild-type embb mutations Colored marker Pre-XDR G Lin 8th TB lab conf 8-19-13 15

Probe-based MDST Detect presence or absence of a mutation(s). Do not inform what the mutation is Assume all mutations are associated with DR. Often true, but not always. When RIF-R rate is 2%, if the specificity is 96%, the PPV is 33%. [CA data] Due to low PPV, when a mutation is detected, confirmation by a sequence-based method is recommended. G Lin 8th TB lab conf 8-19-13 16

GeneXpert No mutations detected in rpob Predict RIF-S, but unable to predict for INH If INH-R is suspected, use other MDST methods HAIN, PSQ or Sanger Mutations detected in rpob If RIF- R is not suspected, confirmation by a SQbased MDST is recommended. If RIF- R is suspected, confirmation by a SQbased MDST is optional. Probe E most common, likely be true + G Lin 8th TB lab conf 8-19-13 17

Sequence-based MDST Sanger sequencing Gold standard http://en.wikipedia.org/wiki/sanger_sequencing Pyrosequencing (PSQ) Realtime sequencing http://www.qiagen.com/media/player.aspx?mov ie=pyrosequencing&width=480&height=380 G Lin 8th TB lab conf 8-19-13 18

Pyrosequencing workflow 1-2h 30-50 min 1 min/base PCR ssdna prep PSQ Amplify target. One primer is biotinylated. Capture ssdna with streptavidin-coated beads. SQ primer anneals to DNA. Realtime sequencing. SQ data generated from the 1st base next to SQ primer. G Lin 8th TB lab conf 8-19-13 19

Below are steps occur in pyrosequencer: 1. Incorporation of dntp generates ppi. 2. APS + ppi ATP, catalyzed by ATP sulfurylase. 3. ATP drives Luciferin oxyluciferin, catalyzed by luciferase. 4. Light generated, proportional to dntp incorporated, recoded by CCD. C G T CC GG A 5. Apyrase degrades unincorporated dntp & ATP. When degradation is complete, another dntp will be added. 6. Pyrogram shows sequential event of dntp incorporated. The peak level is proportional to dntps incorporated. G Lin 8th TB lab conf 8-19-13 20

SQ-based MDST : Transparency with SQ provided Enable to differentiate silent mutations from others. Prevent reporting false-r. New mutations can be detected. Defer interpretation to CDST. Emerging resistance can be recognized to certain extent (5:5 or 4:6, etc.). Allow to study MIC for each mutation This knowledge is accumulable for future use. G Lin 8th TB lab conf 8-19-13 21

SQ-based MDST No mutations detected predicts DS. Mutations detected For known mutations, based on past experience to interpret. All mutations are not equivalent, some may not confer DR. It is advisable to study MIC for each mutation. Silent mutations are not associated with DR. If the association of a mutation with DR is uncertain, defer interpretation to CDST. For new mutations, defer interpretation to CDST. G Lin 8th TB lab conf 8-19-13 22

Recommendations--CDST Two scenarios: If DR detected, but not anticipated Discordant CDST results with different methods or same method. Performing MDST can be helpful If mutation detected, confirms DR results. If mutation not detected, lean toward DS, repeat CDST. Make sure the culture is pure DST is performed properly Drug solution is prepared and added properly Inoculum is prepared properly. G Lin 8th TB lab conf 8-19-13 23

Discordant CDST results: hard to resolve Sometimes even MDST cannot help! Association of some mutations with DR is uncertain! embb mutations may not confer EMB-R rrs 1401A/G msy not confer CAP-R Association of many pnca mutations with PZA-R is still unknown. Problems with test (critical) concentrations? Problems with CDST methods? G Lin 8th TB lab conf 8-19-13 24

Discordant CDST results Flip-floppers Poor reproducibility of CDST may occur when: Some mutations cause MIC elevated slightly but lower than or close to the critical concentration. Some strains with wildtype SQ (or have a mutation somewhere we do not know), but MIC of a drug is close to the critical concentration. G Lin 8th TB lab conf 8-19-13 25

Flip-floppers (examples) rpob 533 CCG & 511CCG Borderline S or low level R. RIF MIC = 0.5 ug/ml by MGIT MGIT: likely to be S. AP: S or R (low % R) rrs 1402C/T AMK-R or S Borderline S or low level R. G Lin 8th TB lab conf 8-19-13 26

Flip-floppers = Borderline?? TB DST does not have borderline category Exception: PZA testing by BACTEC 460. For isolates with flip-flopping results Lab may repeat and repeat, then report R or S based on 2/3 or 3/5 winners. Clinicians takes S or R without knowing the flipflopping nature of the result. Is it advisable to consider borderline for those flip-floppers? When arsenals fall short for difficult TB cases, those flip-floppers may still be useful? G Lin 8th TB lab conf 8-19-13 27

A lot more to research. Microbes are smart! But, we do not give up!! G Lin 8th TB lab conf 8-19-13 28

Thank You! Comments & Questions! G Lin 8th TB lab conf 8-19-13 29